title: [177Lu]DOTA-anti-CD20: labeling and pre-clinical studies.
abstract: Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with (177)Lu through a simple method. [(177)Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [(177)Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
authors.affiliation: Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo, Uruguay. paudicio@cin.edu.uy
authors.forename: Paola F
authors.initials: PF
authors.lastname: Audicio
authors.forename: Gustavo
authors.initials: G
authors.lastname: Castellano
authors.forename: Marcos R
authors.initials: MR
authors.lastname: Tassano
authors.forename: Maria E
authors.initials: ME
authors.lastname: Rezzano
authors.forename: Marcelo
authors.initials: M
authors.lastname: Fernandez
authors.forename: Eloisa
authors.initials: E
authors.lastname: Riva
authors.forename: Ana
authors.initials: A
authors.lastname: Robles
authors.forename: Pablo
authors.initials: P
authors.lastname: Cabral
authors.forename: Henia
authors.initials: H
authors.lastname: Balter
authors.forename: Patricia
authors.initials: P
authors.lastname: Oliver
mesh_terms: D000818:Animals; D008297:Male; D051379:Mice; D009010:Monte Carlo Method; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D019275:Radiopharmaceuticals